Merck
NICE Recommends Novartis' Tafinlar-Mekinist as Frontline Treatment for BRAF-Mutant NSCLC
The agency estimated that the drug combination's cost-effectiveness falls within what it considers an acceptable use of the NHS's resources.
Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test
Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.
The drugmaker is hyping its recent acquisition announcement against an overall 29 percent revenue decline and 4 percent oncology sales dip during Q1 2023.
Merck's Keytruda Sales Grow 20 Percent in Q1 While Overall Revenues Dip 9 Percent
The firm's blockbuster immunotherapy was once again its main growth driver during the first quarter of 2023 as Merck continued expanding its indications.
Trial Assessing if BET Inhibitors Can Make 'Cold' Prostate Cancers Responsive to Immunotherapy
Premium
A Phase II study is to test the efficacy of Zenith Epigenetics' BET inhibitor plus immunotherapy and an androgen therapy in Rb-deficient prostate cancer.